Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,255 Million (Mid Cap)
34.00
NA
0.00%
-0.31
13.58%
4.67
Revenue and Profits:
Net Sales:
360 Million
(Quarterly Results - Mar 2026)
Net Profit:
52 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.8%
0%
-23.8%
6 Months
-38.36%
0%
-38.36%
1 Year
28.65%
0%
28.65%
2 Years
-21.27%
0%
-21.27%
3 Years
60.84%
0%
60.84%
4 Years
244.76%
0%
244.76%
5 Years
270.13%
0%
270.13%
Inner Mongolia Furui Medical Science Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.97%
EBIT Growth (5y)
24.64%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0.77
Tax Ratio
27.81%
Dividend Payout Ratio
25.61%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.67%
ROE (avg)
9.89%
Valuation key factors
Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
4.67
EV to EBIT
21.93
EV to EBITDA
18.26
EV to Capital Employed
6.34
EV to Sales
5.31
PEG Ratio
0.61
Dividend Yield
NA
ROCE (Latest)
28.92%
ROE (Latest)
13.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
360.10
330.40
8.99%
Operating Profit (PBDIT) excl Other Income
68.90
93.30
-26.15%
Interest
0.90
0.60
50.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
52.10
41.70
24.94%
Operating Profit Margin (Excl OI)
191.20%
204.70%
-1.35%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 8.99% vs 3.02% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 24.94% vs -36.24% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,592.80
1,346.30
18.31%
Operating Profit (PBDIT) excl Other Income
504.50
379.90
32.80%
Interest
3.60
3.00
20.00%
Exceptional Items
-13.10
-7.70
-70.13%
Consolidate Net Profit
258.40
195.90
31.90%
Operating Profit Margin (Excl OI)
250.90%
211.50%
3.94%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 18.31% vs 17.77% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 31.90% vs 10.62% in Dec 2024
About Inner Mongolia Furui Medical Science Co., Ltd. 
Inner Mongolia Furui Medical Science Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






